Marine sponge derived eribulin in preclinical and clinical studies for cancer

Handbook of Anticancer Drugs from Marine Origin

Volumn , Issue , 2015, Pages 59-100

  Swami, Umang ^a   Shah, Umang ^b   Goel, Sanjay ^b  

^a ST BARNABAS HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; E7389; Embrace; Eribulin; Halaven ; Halichondrin B; Microtubule inhibitor; Nsc 707389

Indexed keywords

EID: 84940412442     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-07145-9_4     Document Type: Chapter

References (96)

1. Uemura D, Takahashi K, Yamamoto T, Katayama C, Tanaka J, Okumura Y, Hirata Y (1985) Norhalichondrin A: an antitumor polyether macrolide from a marine sponge. J Am Chem Soc 107(16):4796-4798. Doi:10.1021/ja00302a042
2. Hirata Y, Uemura D (1986) Halichondrins—antitumor polyether macrolides from a marine sponge. Pure Appl Chem 58(5):701-710. Doi:10.1351/pac198658050701
3. Pettit GR, Herald CL, Boyd MR, Leet JE, Dufresne C, Doubek DL, Schmidt JM, Cerny RL, Hooper JN, Rutzler KC (1991) Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp. J Med Chem 34(11):3339-3340
4. Pettit GR, Tan R, Gao F, Williams MD, Doubek DL, Boyd MR, Schmidt JM, Chapuis JC, Hamel E (1993) Isolation and structure of halistatin 1 from the eastern Indian Ocean marine sponge Phakellia carteri. J Org Chem 58(9):2538-2543. Doi:10.1021/jo00061a030
5. Gravelos DG, Lake R, Blunt JW, Munro MHG, Litaudon MSP (1993) Halichondrins: cytotoxic polyether macrolides. European Patent Office, Munich, Switzerland: Publication number EP 0 572 109 A1
6. Hamel E (1992) Natural products which interact with tubulin in the vinca domain: may- tansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther 55(1):31-51. Doi:0163-7258(92)90028-X[pii]
7. Bai RL, Paull KD, Herald CL, Malspeis L, Pettit GR, Hamel E (1991) Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 266(24):15882-15889
8. Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, Welsh S, Zheng W, Seletsk BM, Palme MH, Habgood GJ, Singer LA, Dipietro LV, Wang Y, Chen JJ, Quincy DA, Davis A, Yoshimatsu K, Kishi Y, Yu MJ, Littlefield BA (2001) In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 61(3):1013-1021
9. Luduena RF, Roach Mc, Prasad V, Pettit GR (1993) Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin. Biochem Pharmacol 45(2):421-427. Doi:0006-2952(93)90079-C[pii]
10. Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, Desjardins C, Fang F, Jansen M, Shuster DE, Mani S, Takimoto CH (2009) A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 15(12):4207-4212. Doi:1078-0432.CCR-08-2429[pii] 10.1158/1078-0432.CCR-08-2429
11. Fodstad O, Breistol K, Pettit GR, Shoemaker RH, Boyd MR (1996) Comparative antitumor activities of halichondrins and vinblastine against human tumor xenografts. J Exp Ther Oncol 1(2):119-125
12. Aicher TD, Buszek KR, Fang FG, Forsyth CJ, Jung SH, Kishi Y, Matelich Mc, Scola PM, Spero DM, Yoon SK (1992) Total synthesis of halichondrin B and norhalichondrin B. J Am Chem Soc 114(8):3162-3164. Doi:10.1021/ja00034a086
13. Yu MJ, Zheng W, Seletsky BM (2013) From micrograms to grams: scale-up synthesis of eribulin mesylate. Nat Prod Rep 30(9):1158-1164. Doi:10.1039/c3np70051h
14. Swami U, Chaudhary I, Ghalib MH, Goel S (2012) Eribulin—a review of preclinical and clinical studies. Crit Rev Oncol Hematol 81(2):163-184. Doi:10.1016/j.critrevonc.2011.03.002
15. Mani S, Swami U (2010) Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer. Drugs Today (Barc) 46(9):641-653. Doi:1519020[pii]10.1358/dot.2010.46.9.1519020
16. Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4(7):1086-1095. Doi:4/7/1086[pii]10.1158/1535-7163.Mc T-04-0345
17. Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA (2008) Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 7(7):2003-2011. Doi:7/7/2003[pii]10.1158/1535-7163.Mc T-08-0095
18. Dabydeen DA, Burnett JC, Bai R, Verdier-Pinard P, Hickford SJ, Pettit GR, Blunt JW, Munro MH, Gussio R, Hamel E (2006) Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol 70(6):1866-1875. Doi:mol.106.026641[pii]10.1124/mol.106.026641
19. Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, Kishi Y, Yu MJ, Littlefield BA (2004) Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 64(16):5760-5766. Doi:10.1158/0008-5472.CAN-04-1169 64/16/5760[pii]
20. F.D.A. U. S. (2010) Food and drug administration. Http://www.accessdata.fda.gov/drugsatf-da_docs/label/2010/201532lbl.pdf Accessed 16 Nov 2010
21. U. S. National Institutes of Health (2013). Food and drug administration http://clinicaltrials.gov/ct2/results?term=e7389. Accessed 10 Nov 2013
22. Spindeldreier K, Thiesen J, Lipp HP, Kramer I (2013) Physico-chemical stability of eribulin mesylate containing concentrate and ready-to-administer solutions. J Oncol Pharm Pract. 20(3):183-189. Doi:10.1177/1078155213492449
23. Halaven full Prescribing Information (2013). J Oncol Pharm Pract http://halaven.com/sites/default/files/HALA-VEN_full_Prescribing_Information.pdf Accessed 2 Nov 2013
24. National Cancer Institute (2010) Division of Cancer Treatment and Diagnosis-Featured Agents. Http://dctd.cancer.gov/FeaturedAgents/pdfs/E7389SolicitationMarch2005.pdf. Accessed 13 Nov 2010
25. Kimura T, Synold T, Mahaffey CM, Labauve AE, Mack PC, Lenz H-J, Gandara DR, Do-roshow JH, Gumerlock PH (2003) E7389, a novel antimicrotubule agent with potent p53-independent induction of p27, Bcl2 phosphorylation and cytotoxicity in nonsmall cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 22:2003 (abstr 2804)
26. Alley Mc, Smith AC, Donohue SJ, Schweikart KM, Newman DJ, Tomaszewski JE (2005) Comparison of the relative efficacies and toxicities of halichondrin B analogues. 17Th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-18, Philadelphia), Abst C230
27. Budman DR, Calabro A, Littlefield BA (2004) Synergestic combinations of E7389 (halichondrin B analogue) with conventional agaents: In vitro median effect analysis in cell lines with potential clinical implications. 27Th Annu San Antonio Breast Cancer Symp (Dec 8-11, San Antonio). Abst 6055
28. Kuznetsov G, Tendyke K, Yu M, Littlefield BA (2007) Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro. Proc Am Assoc Cancer Res 48:275. Abstract C58
29. Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, Keir ST, Maris JM, Billups CA, Desjardins C, Kurmasheva RT, Houghton PJ, Smith MA (2013) Initial testing (stage 1)of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer 60(8):1325—1332. Doi:10.1002/pbc.24517
30. Luyimbazi D, Luu TH, Xing Q, Yan J, Tully D, Han ES, Yip R, Yim JH (2013) Effect of eribulin on cell growth and PI3K pathway activity with and without RAD001 in triple-negative and HER2-expressing breast cancer. Asco Meeting Abstracts 31(26_suppl):173
31. LaPointe NE, Morfini G, Brady ST, Feinstein SC, Wilson L, Jordan MA (2013) Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology 37:231-239. Doi:10.1016/j.neuro.2013.05.008
32. Towle MJ, Agoulnik S, Kuznetsov G, TenDyke K, Reardon C, Cheng H, Zheng W, Seletsky BM, Palme MH, Kishi Y, Lewis MD, Yu MJ, Littlefield BA (2003) In vivo efficacy of E7389, a synthetic analogue of the marine sponge antitubulin agent halichondrin B, against human tumor xenografts under monotherapy and combination therapy conditions. Proc Am Assoc Cancer Res (AACR) 44(2nd Ed.):Abst 2749
33. Towle MJ, Nomoto K, Asano M, Kishi Y, Yu MJ, Littlefield BA (2012) Broad spectrum pre-clinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions. Anticancer Res 32(5):1611-1619
34. Wozniak KM, Nomoto K, Lapidus RG, Wu Y, Carozzi V, Cavaletti G, Hayakawa K, Hoso-kawa S, Towle MJ, Littlefield BA, Slusher BS (2011) Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice. Cancer Res 71(11):3952— 3962. Doi:10.1158/0008-5472.CAN-10-4184
35. Wozniak KM, Wu Y, Farah MH, Littlefield BA, Nomoto K, Slusher BS (2013) Neuropathy-inducing effects of eribulin mesylate versus paclitaxel in mice with preexisting neuropathy. Neurotox Res 24(3):338—344. Doi:10.1007/s12640-013-9394-3
36. Bai R, Nguyen TL, Burnett JC, Atasoylu O, Munro MH, Pettit GR, Smith AB 3rd, Gussio R, Hamel E (2011) Interactions of halichondrin B and eribulin with tubulin. J Chem Inf Model 51(6):1393—1404. Doi:10.1021/ci200077t
37. Okouneva T, Wilson L, Littlefield BA, Jordan MA (2001) E7389 and ER-076349, synthetic halichondrin B analogs, suppress centromere dynamics in concert with mitotic block. Proc Am Assoc Cancer Res (AACR) 45:Abst 5436
38. Kamath K, Okouneva T, Miller H, Davis C, littlefield BA, Wilson L, Jordan MA (2003) E7389, a synthetic analog of halichondrin B, suppresses microtubule dynamics in living Mc F7 cells by a novel mechanism. Proc Am Assoc Cancer Res (AACR) 44(2nd Ed):Abst LB—43
39. Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, Jordan MA (2010) Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 49(6):1331—1337. Doi:10.1021/bi901810u
40. Alday PH, Correia JJ (2009) Macromolecular interaction of halichondrin B analogues er-ibulin (E7389) and ER-076349 with tubulin by analytical ultracentrifugation. Biochemistry 48(33):7927—7938. Doi:10.1021/bi900776u
41. Smith J, Wilson L, Zhu X, Lewis B, Littlefield B (2008) A JM Eribulin (E7389) binds to 13 saturable sites at microtubule ends to inhibit microtubule dynamics. 99Th AACR Annual Meeting Apr 12—16 98; San Diego, CA. Abstract #1408
42. Agoulnik S, Kuznetsov G, Tendyke K, Parent LA, Marsh JP, Twine N, Renshaw FG, Sil-berman S, Littlefield BA (2005) Sensitivity to halichondrin analog E7389 and hemiasterlin analog E7974 correlates with �III tubulin isotype expression in human breast cancer cell lines. J Clin Oncol ASCO Annual Meeting Proceedings, vol 23, no 16S, Part I of II (June 1 Supplement), 2005:2012
43. Stengel C, Newman SP, Leese MP, Potter BV, Reed MJ, Purohit A (2010) Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer 102(2):316-324. Doi:6605489[pii]10.1038/sj.bjc.6605489
44. Saussede-Aim J, Matera EL, Herveau S, Rouault JP, Ferlini C, Dumontet C (2009) Vinorelbine induces beta3-tubulin gene expression through an AP-1 Site. Anticancer Res 29(8):3003-3009. Doi:29/8/3003[pii]
45. Seve P, Dumontet C (2008) Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 9(2):168-175. Doi:S1470-2045(08)70029-9[pii]10.1016/S1470-2045(08)70029-9
46. Synold TW, Morgan RJ, Newman EM, Lenz HJ, Gandara DR, Colevas AD, Lewis MD, Doroshow JH (2005) A phase I pharmacokinetic and target validation study of the novel antitubulin agent E7389: a California cancer consortium trial. J Clin Oncol ASCO Annu Meet Proc 23(16S June 1 Suppl):3036
47. Synold TW, Lawrence J, Xi B, Colevas AD, Lewis MD, Doroshow JH (2003) Human pharmacokinetics of E7389 (Halichondrin B analog), a novel anti-microtubule agent undergoing phase I investigation in the California Cancer Consortium (CCC). Proc Am Soc Clin Oncol 22:2003 (abstr 575)
48. Tan AR, Rubin EH, Walton DC, Shuster DE, Wong YN, Fang F, Ashworth S, Rosen LS (2009) Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 15(12):4213-4219. Doi:1078-0432.CCR-09-0360[pii]10.1158/1078-0432.CCR-09-0360
49. Mukohara T, Nagai S, Mukai H, Namiki M, Minami H (2012) Eribulin mesylate in patients with refractory cancers: a Phase I study. Investig new drugs 30(5):1926-1933. Doi:10.1007/s10637-011-9741-2
50. Devriese LA, Witteveen PO, Marchetti S, Mergui-Roelvink M, Reyderman L, Wanders J, Jenner A, Edwards G, Beijnen JH, Voest EE, Schellens JH (2012) Pharmacokinetics of er-ibulin mesylate in patients with solid tumors and hepatic impairment. Cancer chemother pharmacol 70(6):823-832. Doi:10.1007/s00280-012-1976-x
51. Devriese LA, Mergui-Roelvink M, Wanders J, Jenner A, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Schellens JH (2013) Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. Invest New Drugs 31(2):381-389. Doi:10.1007/s10637-012-9829-3
52. Devriese LA, Witteveen PE, Wanders J, Law K, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Huitema AD, Voest EE, Schellens JH (2013) Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin. Br J Clin Pharmacol 75(2):507-515. Doi:10.1111/j.1365-2125.2012.04381.x
53. Swami U, Petrylak DP, Raftopoulos H, Shuster DE, Wang G, Kumar V, Martinez G, Goel S, Aisner J (2010) Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 28(15_suppl):2589
54. Jansen M, Vernaz-Gris M, DesJardins C, Wong N, Campone M, Cortes J, Wanders J, Shuster D, Fuseau E (2009) Population pharmacokinetics (PPK) of eribulin mesylate in patients with locally advanced or metastatic breast cancer (MBC). J Clin Oncol (Meeting Abstracts) 27(15S):2524
55. Dubbelman AC, Rosing H, Jansen RS, Mergui-Roelvink M, Huitema AD, Koetz B, Lymbou-ra M, Reyderman L, Lopez-Anaya A, Schellens JH, Beijnen JH (2012) Mass balance study of [(1)(4)C]eribulin in patients with advanced solid tumors. Drug Metab Dispos 40(2):313-321. Doi:10.1124/dmd.111.042762
56. Zheng W, Seletsky BM, Palme MH (2003) Structure-activity relationships of synthetic halichondrin B analog E7389: in vitro susceptibility to PgP-mediated drug efflux. Annu Meet Am Assoc Cancer Res (7):(abstract 2751)
57. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, Poruchynsky MS (1997) Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272(27):17118-17125
58. Zhang ZY, King BM, Pelletier RD, Wong YN (2008) Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Che-mother Pharmacol 62(4):707-716. Doi:10.1007/s00280-008-0755-1
59. Simon R, Rubinstein L, Arbuck SG, Christian Mc, Freidlin B, Collins J (1997) Accelerated Titration Designs for Phase I Clinical Trials in Oncology. J Nat Cancer Inst 89(15):1138-1147. Doi:10.1093/jnci/89.15.1138
60. Synold TW, Tsao-Wei DD, Quinn DI, Groshen SG, Aparicio A, Twardowski P, Stadler WM, Gandara DR, Lara Jr P, Newman EM (2010) Phase I and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts) with renal dysfunction (RD) and advanced urothelial cancer (UC): a California Cancer Consortium Trial. J Clin Oncol 28:7s (suppl; abstr 2527)
61. Goel R, Chen E, Welch S, Laurie S, Siu L, Jonker D, Srinivasan R, Wang L, Ivy P, Oza A (2009) The Princess Margaret Hospital Phase II Consortium (2009) Phase I study of E7389/geMc itabine combination in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 27(15S):e13509
62. Koczywas M, Lenz H-J, Mortimer JE, El-Khoueiry AB, Frankel PH, Gandara DR, Cristea Mc, Chung VM, Lim D, Reckamp KL, Lau DHM, Ye W, Doyle LA, Carroll MI, Newman EM (2013) PHI-55: (NCI#7427): a phase I study of halichondrin B analog (E7389) in combination with cisplatin (CDDP) in advanced solid tumors: a CCC, NCI/CTEP-sponsored trial (grant U01 CA 062505). Asco Meeting Abstracts 31(15_suppl):2564
63. Bono JS de, Molife LR, Sonpavde G, Maroto JP, Calvo E, Cartwright TH, Loesch DM, Feit K, Das A, Zang EA, Wanders J, Agoulnik S, Petrylak DP (2012) Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. Ann Oncol 23(5):1241-1249. Doi:10.1093/annonc/mdr380
64. Stein MN, Chen Y, Hudes GR, Carducci MA, Tan W, DiPaola RS (2010) ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). Asco Meeting Abstracts 28(15_suppl):4556
65. Raftopoulos H, Aisner J, Kumar K, Goel S, Dittrich C, Jain M, Gopalakrishna P, Salazar P Jones B, Petrylak DP (2013) Phase Ib extension study of eribulin mesylate in combination with carboplatin in patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC). Asco Meeting Abstracts 31(15_suppl):e19145
66. Truong T-G, Pelayo M, Grabowsky JA, Melisko ME, Magbanua MJM, Moasser MM, Rein-ert A, Hwang J, Park JW, Munster PN, Rugo HS (2013) Phase Ib study of eribulin (ERB) and cyclophosphamide (CTX) in metastatic breast cancer (MBC). Asco Meeting Abstracts 31(15_suppl):1095
67. Nasim MY, Plummer R, Evans TRJ, Morrison R, Anthoney DA, Haney S, Madi A, Savulsky CI, Johnston C, Carter D, Reyderman L, Gopalakrishna P, Wanders J, Twelves C (2012) A phase Ib dose-escalation study of eribulin mesylate in combination with capecitabine in patients with advanced/metastatic cancer. Asco Meeting Abstracts 30(15):2552
68. Lesimple T, Edeline J, Carrothers TJ, Cvitkovic F, Darpo B, Delord JP, Lena H, Penel N, Edwards GJ, Law K, Wanders J, Kristensen A, Reyderman L (2013) A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors. Invest New Drugs 31(4):900-909. Doi:10.1007/s10637-012-9893-8
69. Quinn DI, Aparicio A, Tsao-Wei DD, Groshen SG, Dorff TB, Synold TW, Stadler WM, Gandara DR, Lara P, Newman EM (2010) California Cancer Consortium (2010) Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)-Final report: A California Cancer Consortium-led NCI/CTEP-sponsored trial. Asco Meeting Abstracts 28(15):4539
70. Vogelzang NJ, Conkling P, Duran I, Maroto JP, Modiano M, De Leonardis P, Hodge JP, Li-eberman R (2012) Phase Ib/II study of eribulin mesylate administered in combination with geMc itabine/cisplatin as first-line therapy for locally advanced or metastatic bladder cancer: Phase Ib results. Asco Meeting Abstracts 30(5_suppl):273
71. Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, Wright J, Tan AR, Dacosta NA, Chuang E, Smith J, O’Shaughnessy J, Shuster DE, Meneses NL, Chandrawansa K, Fang F, Cole PE, Ashworth S, Blum JL (2009) Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 27(18):2954-2961. Doi:JCO.2008.17.7618[pii]10.1200/JCO.2008.17.7618
72. Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roche H, Bachelot T, Awada A, Pari-daens R, Goncalves A, Shuster DE, Wanders J, Fang F, Gurnani R, Richmond E, Cole PE, Ashworth S, Allison MA (2010) Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthra-cycline, a taxane, and capecitabine. J Clin Oncol 28 (25):3922-3928. Doi:JCO.2009.25.8467[pii]10.1200/JCO.2009.25.8467
73. Aogi K, Iwata H, Masuda N, Mukai H, Yoshida M, Rai Y, Taguchi K, Sasaki Y, Takashima S (2012) A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol 23(6):1441-1448. Doi:10.1093/annonc/mdr444
74. Smith JW, Rege J, Maniar H, Song J, Cox D, O’Shaughnessy J (2013) Eribulin mesylate (Erib) plus capecitabine (X) for adjuvant treatment in post-menopausal estrogen receptor-positive (ER+) early-stage breast cancer: Phase II, multicenter, single-arm study. Asco Meeting Abstracts 31(15_suppl):563
75. Vahdat LT, Garcia AA, Vogel C, Pellegrino C, Lindquist DL, Iannotti N, Gopalakrishna P Sparano JA (2013) Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Res Treat 140(2):341-351. Doi:10.1007/s10549-013-2574-2
76. Yardley DA, Osborne CRC, Richards PD, Daniel BR, Danso MA, Favret A, Bromund J, Hsu Y, Ibrahim AB (2012) Interim safety results of eribulin (E) combined with ramucirumab (RAM) in patients (pts) with advanced metastatic breast cancer (MBC). Asco Meeting Abstracts 30(27_suppl):110
77. Spira AI, Iannotti NO, Savin MA, Neubauer M, Gabrail NY, Yanagihara RH, Zang EA, Cole PE, Shuster D, Das A (2012) A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer. Clin Lung Cancer 13 (1): 31-38. Doi:10.1016/j.cllc.2011.06.010
78. Gitlitz BJ, Tsao-Wei DD, Groshen S, Davies A, Koczywas M, Belani CP, Argiris A, Ramalin-gam S, Vokes EE, Edelman M, Hoffman P, Ballas MS, Liu SV, Gandara DR (2012) A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced nonsmall cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol 7(3):574-578. Doi:10.1097/JTO.0b013e31823f43ca
79. Hensley ML, Kravetz S, Jia X, Iasonos A, Tew W, Pereira L, Sabbatini P, Whalen C, Agha-janian CA, Zarwan C, Berlin S (2012) Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study. Cancer 118(9):2403-2410. Doi:10.1002/cncr.26569
80. Ikeda Y, Takano M, Sasaki N, Kita T, Kikuchi Y, Kudoh K (2013) Effect of weekly administration of bevacizumab, eribulin, and oxalilplatin in patients with heavily pretreated serous ovarian carcinoma. Asco Meeting Abstracts 31(15_suppl):e16506
81. Schoffski P, Ray-Coquard IL, Cioffi A, Bui NB, Bauer S, Hartmann JT, Krarup-Hansen A, Grunwald V, Sciot R, Dumez H, Blay JY, Le Cesne A, Wanders J, Hayward C, Marreaud S, Ouali M, Hohenberger P (2011) Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol 12(11):1045-1052. Doi:10.1016/S1470-2045(11)70230-3
82. Wozniak A, Wiemer EAC, Burger H, Allemeersch J, van Eijsden R, Mathijssen RHJ, Sleijfer S, Smid M, Floris G, Marreaud S, Nzokirantevye A, Sciot R, Schoffski P (2013) Identification of potential molecular biomarkers for response of soft tissue sarcoma to eribulin: translational results of EORTC trial 62052. Asco Meeting Abstracts 31(15):10573
83. Renouf DJ, Tang PA, Major P, Krzyzanowska MK, Dhesy-Thind B, Goffin JR, Hedley D, Wang L, Doyle L, Moore MJ (2012) A phase II study of the halichondrin B analog er-ibulin mesylate in geMc itabine refractory advanced pancreatic cancer. Invest New Drugs 30(3):1203-1207. Doi:10.1007/s10637-011-9673-x
84. Arnold SM, Moon J, Williamson SK, Atkins JN, Ou SH, Leblanc M, Urba SG (2009) Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618. Invest New Drugs 29(2):352-359. Doi:10.1007/s10637-009-9348-z
85. Cortes J, O’ Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Dieras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C (2011) Eribulin monotherapy versus treatment of physician’ s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377(9769):914-923. Doi:10.1016/S0140-6736(11)60070-6
86. Twelves C, Akerele C, Wanders J, Cortes J (2010) Investigators obotS Eribulin Mesylate (E7389) vs. Treatment of Physician’ s Choice (TPC) in Patients (Pts) with Metastatic Breast Cancer (MBC): subgroup analyses from the EMBRACE Study. Abstract 2750, presented at the ESMO Congress, 8th September 2010, Milan, Italy. Ann Oncol 21(Suppl 8):viii96-viii121. Doi:10.1093/annonc/mdq517
87. Twelves C, Vahdat LT, Cortes J, Wanders J, Dutcus CE, Seegobin S, Muss HB (2011) The relationship between age and survival outcomes for eribulin in metastatic breast cancer. Asco Meeting Abstracts 29(15_suppl):1060
88. Faria C, Li X, Powers A, Vahdat LT (2013) Effects of dose modification of eribulin mesylate in patients with locally recurrent or metastatic breast cancer. Asco Meeting Abstracts 31(26_suppl):157
89. Kaufman P, Awada A, Twelves C, Yelle L, Perez E, Wanders J, Olivo M, He Y, Dutcus C (2012) A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Res 72(24 Suppl):S6-S6. Doi:10.1158/0008-5472.Sabcs12-s6-6
90. Cortes J, Awada A, Kaufman PA, Yelle L, Perez EA, Velikova G, Wanders J, Olivo MS, He Y, Dutcus C, Simons WR, Twelves C (2013) Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: A phase III, open-label, randomized study. Asco Meeting Abstracts 31(15_suppl):1050
91. Kaufman PA, Cortes J, Awada A, Yelle L, Perez EA, Wanders J, Olivo MS, He Y, Dutcus C, Twelves C (2013) A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: Subgroup analyses. Asco Meeting Abstracts 31(15_suppl):1049
92. Pean E, Klaar S, Berglund EG, Salmonson T, Borregaard J, Hofland KF, Ersboll J, Abadie E, Giuliani R, Pignatti F (2012) The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use. Clin Cancer Res 18(17):4491-4497. Doi:10.1158/1078-0432-CCR-11-3075
93. Narayan S, Carlson EM, Cheng H, Condon K, Du H, Eckley S, Hu Y, Jiang Y, Kumar V, Lewis BM, Saxton P, Schuck E, Seletsky BM, Tendyke K, Zhang H, Zheng W, Littlefield BA, Towle MJ, Yu MJ (2011) Novel second generation analogs of eribulin. Part II: orally available and active against resistant tumors in vivo. Bioorg Med Chem Lett 21(6):1634-1638. Doi:10.1016/j.bMc l.2011.01.097
94. Yu MJ, Zheng W, Tendyke K (2012) Atom-based enumeration: new eribulin analogues with low susceptibility to P-glycoprotein-mediated drug efflux. Bioorg Med Chem Lett 22(24):7363-7366. Doi:10.1016/j.bMc l.2012.10.077
95. Yu Y, Desjardins C, Saxton P, Lai G, Schuck E, Wong YN (2013) Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice. Int J Pharm 443(1-2):9-16. Doi:10.1016/j.ijpharm.2013.01.010
96. Shablak A (2013) Eribulin for advanced breast cancer: a drug evaluation. J Breast Cancer 16(1):12-15. Doi:10.4048/jbc.2013.16.1.12